Title Page:

Title: Real world outcomes of ocriplasmin use by members of the British and Eire Association of Vitreoretinal Surgeons (BEAVRS).

Running Title: BEAVRS ocriplasmin Survey.

Authors:

Richard John Haynes¹ MD FRCOphth
David Yorston³ FRCOphth
D Alistair H Laidlaw⁴ MD FRCOphth
Johann Keller¹ FRCOphth
David HW Steel² FRCOphth

1. Bristol Eye Hospital, Bristol, UK.
2. Sunderland Eye Infirmary, Sunderland, UK and Institute of Genetic Medicine, Newcastle University, Newcastle Upon Tyne, UK.
3. BEAVRS Research Lead & Gartnavel Hospital Glasgow.
4. BEAVRS President & St Thomas’ Hospital, London and The Maidstone Hospital, Kent, UK.

Correspondence to:

Mr Richard J Haynes
Conflict of Interest statement and Financial Disclosures of the authors are listed below:

RJ Haynes – Alcon ocriplasmin advisory board member
DH Steel – Alcon Consultancy, Research funding
DAH Laidlaw - Alcon ocriplasmin advisory board member

This work received no support in the form of grants, equipment or drugs.

Abstract.

Purpose
To describe a survey of the use of ocriplasmin by members of the British & Eire Association of Vitreo-Retinal Surgeons (BEAVRS) for Vitreo-Macular Traction (VMT) and Full Thickness Macular Hole (FTMH) and compare it to published MIVI-TRUST trial data.

Methods
All 173 BEAVRS members were contacted by email in October 2014 requesting data on all cases treated with ocriplasmin up to that date. The total number of cases, FTMH closure rate, VMT release rate and the frequency of adverse events were recorded. Results were compared to trial data.
Results

48 members responded reporting results from 241 eyes. The respective BEAVRS and MIVI-TRUST trial closure rates for small FTMHs were 42.1% and 58.3% (p=0.09) and for medium FTMH 12.7% and 36.7% (p=0.01). The respective VMT release rates were 34.1% and 37.4% (p=NS). Retinal detachment was observed in 3.3% of the BEAVRS cohort compared with 0.4% in MIVI-TRUST. Reduction in visual acuity to < 6/60 was observed in 5.8% of the BEAVRS cohort and 0.6% in MIVI-TRUST. Other complications not reported in the MIVI-TRUST trial included an increase in FTMH basal diameter following unsuccessful ocriplasmin use in 46.9% of BEAVRS cases and zonular instability at the time of subsequent phacoemulsification in 2.4%.

Conclusion

Macular hole closure rates were lower in the BEAVRS survey than published in the MIVI-TRUST trial data. The incidence of adverse events was greater than previously reported. The reasons for these disparities are unknown but could include positive reporting bias inherent to retrospective surveys, treatment and population differences.

Introduction

Ocriplasmin is a first in class agent licensed within Europe in January 2013 for the pharmacological treatment of Vitreo Macular Traction (VMT) including that associated with full thickness macular holes (FTMH).
The efficacy and side effect profile of ocriplasmin had been demonstrated in the Microplasmin for Intravitreous Injection — Traction Release without Surgical Treatment (MIVI-TRUST) pivotal trials (TG-MV-006 and TG-MV-007) reported in August 2012. The authors concluded that ‘Intravitreal injection of ocriplasmin was superior to injection of placebo in altering the vitreoretinal interface of affected eyes, although it was accompanied by some, mainly transient, ocular adverse events.’ Separate analysis of the safety data concluded “Ocriplasmin seems to be generally safe and well tolerated”. A subsequent publication performed a sub group analysis of the MIVI-TRUST data in which macular holes were divided into small and medium sized holes, that is those with an internal diameter or <250 microns or between 250 and 400 microns respectively. Based upon these data ocriplasmin was recommended in October 2013 by the National Institute for Health and Care Excellence (NICE) for use within the NHS in England. Prior to this recommendation the post licensing use of ocriplasmin by BEAVRS members was limited to the minority private healthcare sector.

Anecdotal reports of adverse events combined with early reports in the literature of previously unreported side effects, such as enlargement of the macular hole, zonular instability, and localised non-rhegmatogenous retinal detachment prompted this survey of all BEAVRS members. The aim of this study was to ascertain the effectiveness of ocriplasmin and the incidence of adverse events in normal clinical practice. To date no systematic national post marketing surveillance studies have been reported.
Methods

All 173 BEAVRS members (including 120 consultants) with a registered email address were contacted electronically in October 2014. They were asked to report all cases of vitreomacular traction (VMT) with or without full thickness macular holes (FTMH) that they had treated with ocriplasmin. Members were requested to complete a simple spreadsheet (Table 1). The dataset included the total number of cases they had treated with ocriplasmin, the case mix divided into small FTMH (<250 microns), medium FTMH (>250 and <400 microns) or pure VMT without FTMH, and the proportion with a successful anatomical outcome (i.e. closure of FTMH or release of VMT). Adverse events surveyed included reduction in visual acuity to less than 6/60 Snellen, severe photopsia, photophobia, dyschromatopsia*, pain, retinal tear and/or retinal detachment, changes in the outer segment ellipsoid layer on optical coherence tomography*, electro retinogram changes*, increase in measured macular hole basal diameter*, zonular instability during subsequent cataract surgery* and subsequent failure of macular hole surgery*. Items marked with an asterisk were not reported in the MIVI-TRUST publications.

A second email was sent in January 2015 to collect additional cases and remind contributors of the importance of including data on all cases treated, without selection. Chi squared tests for differences in proportion were employed.

Results

Forty-one members responded to the survey that they had used ocriplasmin, in addition, 7 members responded that they had not used ocriplasmin (even though this was not an
option in the survey) representing an overall response rate from consultant members of 40%. In the UK non-consultants would be unlikely to use ocriplasmin without consultant supervision, in addition at the time of surveying many consultant BEAVRS had not used ocriplasmin but the exact number is unknown as the survey did not ask this. However, at the BEAVRS meeting in 2014 there was an ‘ask the audience’ question about the preferred treatment option for a patient with a small FTMH - 66% voted surgery, 8% voted ocriplasmin and 26% voted observation, suggesting a low usage of ocriplasmin by BEAVRS at the time, consistent with the survey results. A total of 241 eyes were reported to have been injected with ocriplasmin. The distribution of cases is shown in Table 2. The respective BEAVRS and MIVI-TRUST closure rates of small FTMHs were 42.1% and 58.3% (p=0.09) and for medium sized FTMH 12.7% and 36.7% (p=0.01). The outcomes for resolution of VMT were similar to the MIVI-TRUST findings with successful resolution of VMT in 34.1% & 37.4% respectively. A summary of the BEAVRS results with the percentages of each outcome relative to the total number of BEAVRS cases and the equivalent MIVI-TRUST percentage results for comparison are shown in Table 2. Profound drop in vision to <6/60 was reported in 5.8% of cases, with one case falling temporarily to perception of light only (PL) for 24 hours. 11.6% of patients in the BEAVRS cohort experienced severe photopsia. Photopsia was described by some patients as like a ‘snow storm’ or a ‘poorly tuned TV’ and by others as like a ‘New Year’s Eve firework display’. Dyschromatopsia (mainly yellowing or dimming of vision) was reported in 6.2% of BEAVRS ocriplasmin cases. Changes in the outer segment ellipsoid layer on OCT were identified in 10.4%. Ocriplasmin treatment of FTMH failed in 81/112 cases (72%); in these failed cases widening of the macular hole basal diameter on OCT scanning was reported in 46.9% (Figure 1). In one case sub-retinal fluid / lucency was identified in a
region distal to the MH around the optic nerve, including on the nasal side of the nerve (Figure 2).

ERG changes were reported in six cases, however ERGs were only performed in some of the cases that reported marked visual loss. The reported ERG changes consisted of a marked reduction in a and b wave amplitudes and loss of oscillatory potentials suggesting widespread retinal dysfunction in all cases reported (Figure 3). We have no detailed data on how rapidly the ERG changes developed or the speed of recovery other than to say that the effect was prominent enough to be detected between two and three weeks after the ocriplasmin injection and in a few cases a relative suppression of the waveforms (compared to the untreated eye) was still present as far as 12 months after the ocriplasmin injection.

Zonular dialysis was reported in four cases following ocriplasmin. Two cases occurred at the time of combined phacoemulsification + lens implant + pars plana vitrectomy surgery for macular holes that had failed to respond to ocriplasmin treatment. The vitrectomy and phacoemulsification surgery in each case was reported as uneventful, however partial zonular dialysis occurred in one case during intraocular lens injection into the capsular bag. In the second case complete zonular rupture occurred during lens injection necessitating complete removal of the lens and capsular bag and insertion of an iris clip lens. The third case occurred during cataract surgery performed several months after a vitrectomy and gas repair of a retinal detachment subsequent to ocriplasmin injection. In this case the zonules appeared to be absent in one quadrant at the beginning of the phacoemulsification.

Phacodonesis had not been noted preoperatively. The fourth case occurred during the
irrigation / aspiration step of cataract surgery performed 12 months after vitrectomy performed for persistent VMT following ocriplasmin.

Retinal detachment was found in 8 out of 241 (3.3%) cases reported. There were no post injection retinal tears that did not progress to retinal detachment.

Discussion

The reported efficacy from the BEAVRS cohort was similar to that in the MIVI-TRUST phase 3 trials for resolution of VMT. However, the BEAVRS rate of closure of medium sized macular holes was significantly lower than published data (p=0.01). Interestingly only 19 eyes in the MIVI-TRUST trials had medium sized FTMHs as compared to the larger sample size of 55 in the BEAVRS cohort.

There was a higher than expected incidence of ocriplasmin related side effects reported in the BEAVS survey. These include changes in the ellipsoid zone, widening of the basal diameter of macular holes in which ocriplasmin treatment was unsuccessful, ERG abnormalities, the observation of localised non-rhegmatogenous retinal detachment, and the development of a rhegmatogenous retinal detachment in all cases where a post ocriplasmin retinal tear occurred. Grouped together these observations indicate ocriplasmin has a more widespread action than the target vitreoretinal interface, and are suggestive of enzyme action both within the retina and the sub-retinal space, rather than just at the target vitreo-retinal interface. Muller glial cell disruption and subsequent recovery (being the only cell type capable of regeneration within the retina) has been proposed as the basis for the electrophysiological changes, as the ERG has been reported to recover over a period
of months following ocriplasmin injection. Laminin and fibronectin are found in the inter-
photoreceptor matrix and contribute to retinal adhesion. It is possible that ocriplasmin

gains access to the sub-retinal space via the macular hole, however with a molecular weight

of 27.2 kDa it may be a small enough molecule to penetrate through the retina\(^9\). This trans-

retinal route would explain the observation of sub-retinal fluid around the optic nerve head

including on the nasal side of the nerve\(^7\). Further evidence for an adverse effect on retinal

adhesion is that all eight of the BEAVRS cases with a retinal tear went on to develop a retinal
detachment, whereas natural history studies of spontaneous posterior vitreous detachment

suggest that only 30-50% of tears progress to retinal detachment\(^{10,11,12}\).

The 46.9% incidence of widening of the FTMH basal diameter in failed ocriplasmin cases
could have implications for visual outcomes, as increased basal diameter has previously

been found to predict worse post-operative vision\(^{13}\), however, this was not found in the

MIVI-TRUST trials where the acuity improvement in failed ocriplasmin eyes was the same as

in placebo treated eyes.\(^{14,15}\) There is uncertainty as to the cause of the observed widened

basal diameter. It has been hypothesised that it may relate to the effect of increased

vitreous traction on the hole during vitreolysis\(^{16}\). However the extent of widening does not

vary with the degree of VMT release, which might have been expected if this was the cause

and furthermore no increase in base diameter has been observed on intraoperative OCTs

performed during surgery with either posterior hyaloid face separation or ILM peeling\(^{17,18}\).

As with the other outer retinal changes associated with ocriplasmin, widening of the basal
diameter is likely to be due to the proteolytic action of ocriplasmin on laminin in the

interphotoreceptor matrix, which is partly responsible for adhesion of the retina to the RPE.
The observed 3.3% rate of retinal detachment in the BEAVRS cohort is much higher than the 0.4% reported in the MIVI-TRUST report. A contributing factor to this discrepancy may be that the MIVI-TRUST phase 3 trials of ocriplasmin excluded patients with high myopia, one of the BEAVRS retinal detachments observed was in a patient with -9 dioptres of myopia. Exclusion of this individual results in a 2.9% rate of retinal detachment within the BEAVRS cohort compared to 0.4% in the published trials. There are a number of other possible reasons for differences between the BEAVRS and MIVI-Trust data. The BEAVRS survey was retrospective and only 40% of consultant members contributed. It was performed 20 months after European licensing and one year after recommendation by NICE for use on the NHS in England. The disparity in the reported results may arise from positive reporting bias by members who were disappointed with their results\textsuperscript{19}. Similarly the respondents may have under-reported the total number of cases that they had performed. Either error would lead to a higher proportion of complications or treatment failures. Attempts were made to overcome these biases by reminding members to report all cases to maximise the denominator. The BEAVRS results may also be subject to negative reporting bias with underestimation of the incidence of adverse events. Not all patients will have reported their symptoms or had them systematically recorded in the case notes. In addition, only a few patients underwent ERG tests and not all clinicians would have rigorously measured MH basal diameter. This is however the largest reported cohort to date reporting real world outcomes of ocriplasmin. The reduced rate of closure in medium sized FTMH seen in the BEAVRS cohort could be explained by larger diameters within the BEAVRS medium sized FTMH group compared to the MIVI-TRUST cohort, but data to support or refute this are not available in either series.
Unlike the MIVI-TRUST trials, no eyes had ERMs pre-injection, as UK NICE guidelines exclude patients from treatment with ocriplasmin if there is any ERM present.

Differences in injection technique could be important. Ocriplasmin is stored at -25°C in an acidic pH. Once warmed and diluted with non-buffered saline, it starts to autolyse and has a rapid degradation profile within the eye. Differences in injection timing, and location within the vitreous cavity, could lead to variations in outcome. It is recommended that ocriplasmin is given with a 13mm 30 gauge needle fully entered into the eye, but we have no knowledge of whether this was standard practice. Too anterior a location may reduce efficacy at the vitreo-retinal interface, but increase the risk of zonule weakness. Zonule dehiscence was not reported in the MIVI-TRUST data, and may be underestimated as zonular instability may not become apparent until cataract surgery is performed in larger numbers in the future.

Other possible explanations for the variation in efficacy and side effects observed may exist in the biological action of ocriplasmin on the multiple forms of laminin present in the human retina. These splice variants may be subject to genetic variation within and between different populations.

In conclusion in this retrospective email survey of BEAVRS members we found both a higher incidence of adverse events after ocriplasmin, and lower success rates for macular hole closure, than described in the phase 3 trials. Further real world studies are recommended to further clarify the safety and efficacy of ocriplasmin.
Acknowledgements


Conflict of Interest statement and Financial Disclosures of the authors are listed below:

RJ Haynes– Alcon ocriplasmin advisory board member
D Steel– Alcon Consultancy, Research funding
DAH Laidlaw- Alcon ocriplasmin advisory board member

This work received no support in the form of grants, equipment or drugs.

References


**Titles and legends to figures**
Table 1. BEAVRS survey spreadsheet.

Table 2. Results of BEAVRS survey with equivalent percentages from MIVI TRUST trials for comparison.

Figure 1. Widening of the MH basal diameter following ocriplasmin.

Before ocriplasmin. After ocriplasmin

Figure 2. Sub-retinal fluid around the optic nerve, including on the nasal side of the nerve following ocriplasmin.

Figure 3. ERG changes following ocriplasmin showing a marked reduction in dark adapted A and B wave amplitudes and loss of oscillatory potentials.